Tags

Type your tag names separated by a space and hit enter

Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
Future Med Chem. 2016 04; 8(5):527-44.FM

Abstract

Research on the field of metal complexes for the treatment of cancer diseases has attracted increasing interest due to the urgency in finding more efficient and selective treatments. Owing to their wide structural diversity, organometallic complexes appear as potential alternatives to the design of new anticancer candidates. Herein, we review recent progress in our work toward the development of new drugs based on Ru(II)- and Fe(II)-cyclopentadienyl scaffolds. Their design and chemical properties are reviewed and correlated with their biological effects, in particular the key role that coligands play in the overall behavior of the complex.

Authors+Show Affiliations

Centro de Química Estrutural, Faculdade de Ciências da Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal. Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisboa, Portugal.Centro de Química Estrutural, Faculdade de Ciências da Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal.Centro de Química Estrutural, Faculdade de Ciências da Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal.Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, E.N.10, 2695-066 Bobadela LRS, Portugal.Centro de Química Estrutural, Faculdade de Ciências da Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27096164

Citation

Morais, Tânia S., et al. "Tracking Antitumor Metallodrugs: Promising Agents With the Ru(II)- and Fe(II)-cyclopentadienyl Scaffolds." Future Medicinal Chemistry, vol. 8, no. 5, 2016, pp. 527-44.
Morais TS, Valente A, Tomaz AI, et al. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds. Future Med Chem. 2016;8(5):527-44.
Morais, T. S., Valente, A., Tomaz, A. I., Marques, F., & Garcia, M. H. (2016). Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds. Future Medicinal Chemistry, 8(5), 527-44. https://doi.org/10.4155/fmc.16.7
Morais TS, et al. Tracking Antitumor Metallodrugs: Promising Agents With the Ru(II)- and Fe(II)-cyclopentadienyl Scaffolds. Future Med Chem. 2016;8(5):527-44. PubMed PMID: 27096164.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds. AU - Morais,Tânia S, AU - Valente,Andreia, AU - Tomaz,Ana Isabel, AU - Marques,Fernanda, AU - Garcia,Maria Helena, Y1 - 2016/04/20/ PY - 2016/4/21/entrez PY - 2016/4/21/pubmed PY - 2017/7/19/medline KW - anticancer KW - cellular uptake KW - cyclopentadienyl KW - cytotoxicity KW - iron(II) KW - molecular targets KW - organometallic KW - ruthenium(II) SP - 527 EP - 44 JF - Future medicinal chemistry JO - Future Med Chem VL - 8 IS - 5 N2 - Research on the field of metal complexes for the treatment of cancer diseases has attracted increasing interest due to the urgency in finding more efficient and selective treatments. Owing to their wide structural diversity, organometallic complexes appear as potential alternatives to the design of new anticancer candidates. Herein, we review recent progress in our work toward the development of new drugs based on Ru(II)- and Fe(II)-cyclopentadienyl scaffolds. Their design and chemical properties are reviewed and correlated with their biological effects, in particular the key role that coligands play in the overall behavior of the complex. SN - 1756-8927 UR - https://www.unboundmedicine.com/medline/citation/27096164/Tracking_antitumor_metallodrugs:_promising_agents_with_the_Ru_II___and_Fe_II__cyclopentadienyl_scaffolds_ L2 - https://www.future-science.com/doi/full/10.4155/fmc.16.7?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -